Leucovorin calcium/Levoleucovorin

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Colorectal Neoplasms

Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

RecruitingNCT06662786

Janssen Research & Development, LLCColorectal Neoplasms

Start: 2024-10-18End: 2032-01-20Target: 1000Updated: 2026-08-28

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

RecruitingNCT06750094

Janssen Research & Development, LLCColorectal Neoplasms

Start: 2024-12-12End: 2029-04-13Target: 700Updated: 2026-08-28

Related Papers

Abstract CT216: OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer

Cancer Research2026-04-17

Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer

Cancer Research2026-04-17

OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic <i>RAS/BRAF</i> wild-type colorectal cancer.

Journal of Clinical Oncology2025-05-281 citations

OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer.

Journal of Clinical Oncology2025-05-28